Yu D - Search Results

1

Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.

Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Wang H, et al. Among authors: yu d. Int J Oncol. 2002 Jul;21(1):73-80. Int J Oncol. 2002. PMID: 12063552

2

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: yu d. Int J Oncol. 2002 Apr;20(4):745-52. Int J Oncol. 2002. PMID: 11894120

3

GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.

Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, Chen SF. Agrawal S, et al. Among authors: yu d. Int J Oncol. 2002 Jul;21(1):65-72. Int J Oncol. 2002. PMID: 12063551

4

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Wang H, et al. Among authors: yu d. Mol Med. 2002 Apr;8(4):185-99. Mol Med. 2002. PMID: 12149568 Free PMC article.

5

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

Wang H, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: yu d. Prostate. 2003 Feb 15;54(3):194-205. doi: 10.1002/pros.10187. Prostate. 2003. PMID: 12518324

6

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.

Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R. Zhang Z, et al. Among authors: yu d. Clin Cancer Res. 2004 Feb 15;10(4):1263-73. doi: 10.1158/1078-0432.ccr-0245-03. Clin Cancer Res. 2004. PMID: 14977824

7

Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: yu d. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13989-94. doi: 10.1073/pnas.96.24.13989. Proc Natl Acad Sci U S A. 1999. PMID: 10570186 Free PMC article.

8

Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

Agrawal S, Kandimalla ER, Yu D, Hollister BA, Chen SF, Dexter DL, Alford TL, Hill B, Bailey KS, Bono CP, Knoerzer DL, Morton PA. Agrawal S, et al. Among authors: yu d. Int J Oncol. 2001 May;18(5):1061-9. doi: 10.3892/ijo.18.5.1061. Int J Oncol. 2001. PMID: 11295057

9

Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.

Wang H, Nan L, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: yu d. Clin Cancer Res. 2001 Nov;7(11):3613-24. Clin Cancer Res. 2001. PMID: 11705884

10

Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.

Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Wang D, et al. Among authors: yu d. Int J Oncol. 2004 Apr;24(4):901-8. Int J Oncol. 2004. PMID: 15010828

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,644 results

Search Page

Filters